This compound is primarily used in the development of PROTAC (Proteolysis Targeting Chimeras) technology, which is a cutting-edge approach in targeted protein degradation. It functions by binding to the SMARCA2/4 proteins, which are part of the chromatin remodeling complex, and recruits an E3 ubiquitin ligase to tag these proteins for degradation by the proteasome. This mechanism is particularly valuable in cancer research, as it allows for the selective degradation of proteins that are difficult to target with traditional inhibitors. By degrading these proteins, it can potentially disrupt cancer cell proliferation and survival, offering a novel therapeutic strategy for treating various cancers, especially those driven by aberrant chromatin remodeling. Its application extends to preclinical studies aimed at understanding the role of SMARCA2/4 in disease and evaluating the efficacy of PROTAC-based therapies.